These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Preliminary results on the use of Ca 15-3 in malignant ovarian pathology. Ferdeghini M; Gadducci A; Romagnoli S; Bartolini T; Facchini V; Scatena P; Bianchi R; Fioretti P J Nucl Med Allied Sci; 1987; 31(4):299-302. PubMed ID: 3481812 [No Abstract] [Full Text] [Related]
27. [Thomsen antigen in human normal and tumor tissues]. Berdinskikh MS; Pavliuchenkova RP; Kiseleva AS; Kulakova AM; Kosiakov PN Biull Eksp Biol Med; 1983 Mar; 95(3):59-61. PubMed ID: 6830988 [TBL] [Abstract][Full Text] [Related]
28. Risks associated with blood transfusion in newborn infants. Blajchman MA; Sheridan D; Rawls WE Clin Perinatol; 1984 Jun; 11(2):403-15. PubMed ID: 6086206 [TBL] [Abstract][Full Text] [Related]
29. [Correlation between the levels of CA 19-9 and Ca-50 in colorectal cancer]. Lamíquiz Vallejo A; Domínguez Merru-Urrutia MJ; Loizate Totoricagüena A; Cruz Fombellida Cortázar J Med Clin (Barc); 1988 Jan; 90(1):42. PubMed ID: 3162290 [No Abstract] [Full Text] [Related]
30. Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects. Stelljes M; Specht C; Albring J; Volkmann S; Schlösser V; Pauels HG; Poremba C; Bisping G; Opitz C; Scheffold C; Silling G; Kiehl M; Berdel WE; Kienast J Transplantation; 2007 Feb; 83(3):314-22. PubMed ID: 17297406 [TBL] [Abstract][Full Text] [Related]
31. [Introduction of a new laboratory marker for cancer of the pancreas (CA 19.9). Current experience]. Nunes AP; Jukemura J; Machado MC; Scheinberg MA Rev Paul Med; 1986; 104(2):99-101. PubMed ID: 3468583 [No Abstract] [Full Text] [Related]
32. [Isomerization of trifluoroacetamidopropyl-2-acetamido-2-deoxy-D- galactopyranoside into alpha-anomer. A convenient method of synthesis of the artificial T-antigen]. Bovin NV; Zemlianukhina TV; Khorlin AIa Bioorg Khim; 1986 Apr; 12(4):533-8. PubMed ID: 3718549 [TBL] [Abstract][Full Text] [Related]
33. [Significance of a new tumor marker (CA 19-9) in the differential diagnosis of pathological changes in the pancreas detected by ultrasonic diagnosis]. Bohár L; Szilvási I; Bodorné N; Varsányi N; Barda L; Sarkadi G Orv Hetil; 1985 Oct; 126(41):2525-7. PubMed ID: 3900874 [No Abstract] [Full Text] [Related]
34. [The tumor-associated antigen CA 19-9 in the differential diagnosis and course control of malignancies of the pancreas and the gastrointestinal tract]. Klapdor R; Greten H Dtsch Med Wochenschr; 1984 Dec; 109(50):1935-9. PubMed ID: 6210188 [No Abstract] [Full Text] [Related]
35. Reduced acute phase response to differentiate between viral and bacterial infections in children. Urbach J; Rotstein R; Fusman R; Zeltser D; Shapira I; Branski D; Berliner S Pediatr Pathol Mol Med; 2002; 21(6):557-67. PubMed ID: 12537773 [TBL] [Abstract][Full Text] [Related]
36. [Significance of CA-125 antigen in the monitoring of therapy and clinical course of ovarian cancer]. Pulay T; Csömör S Orv Hetil; 1987 Dec; 128(50):2615-9. PubMed ID: 3323994 [No Abstract] [Full Text] [Related]
37. [Human breast cancer markers]. Remennik LV Eksp Onkol; 1985; 7(4):3-8. PubMed ID: 2994992 [TBL] [Abstract][Full Text] [Related]